{"DataElement":{"publicId":"7414245","version":"1","preferredName":"Pegaspargase Dose Control Reason Specify","preferredDefinition":"An explanation of why Pegaspargase dose was capped.","longName":"PEG_DOSE_CTRL_SPEC","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7414240","version":"1","preferredName":"Pegaspargase Dose Control","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)_A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.","longName":"7391860v1.0:7414238v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7391860","version":"1","preferredName":"Pegaspargase","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","longName":"C1200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC9791F-8A7D-4343-E053-4EBD850AD386","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7414238","version":"1","preferredName":"Dose Control","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.:The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.","longName":"C25488:C61299","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Control","conceptCode":"C61299","definition":"The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE4DB12-0144-41B5-E053-4EBD850A47F8","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE4DB12-0155-41B5-E053-4EBD850A47F8","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"SETRAKIN","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7414244","version":"1","preferredName":"Dose Control Reason Specify","preferredDefinition":"Be specific about something; define clearly.","longName":"7414244v1.0","context":"COG","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2390957","version":"1","preferredName":"Specify","preferredDefinition":"Specify; be specific about something; define clearly.","longName":"C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FEED0CD5-44DE-6158-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-08-22","modifiedBy":"ONEDATA","dateModified":"2005-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE4FA88-55CF-428E-E053-4EBD850A96C8","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"SETRAKIN","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Other, specify:","type":"Preferred Question Text","description":"Other, specify:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE4FF51-62A3-431B-E053-4EBD850A74E5","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"SETRAKIN","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}